{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T13:12:20Z","timestamp":1788873140351,"version":"build-2803163510"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hypercalcemia after a burn injury is attributed to bone resorption secondary to muscle inactivity and prolonged immobilization. Evidence to guide treatment is extremely limited. The purpose of this study was to assess the effect of pamidronate on hypercalcemia in patients with burn injuries. This retrospective, observational study was conducted at a regional burn center. Adult patients admitted to the burn surgery service who received IV pamidronate for hypercalcemia during hospitalization were included. The primary outcome was the change in ionized calcium (iCa) at days 7 and 14 after pamidronate treatment. Secondary outcomes included hypocalcemia and the requirement for calcium replacement. Descriptive statistics were used to evaluate the outcomes. Mixed-effects regression analyses were performed to estimate the direction and magnitude of the effects of clinical factors on changes in iCa. Twenty-seven patients and 37 courses of therapy were included for analysis. The mean age was 44.4\u2009\u00b1\u200916.0\u00a0years, 85% were male, and the mean total body surface area (TBSA) burned was 60.2\u2009\u00b1\u200922.2%. The majority of IV pamidronate doses were 30\u00a0mg (96.2%). The mean peak iCa was 1.45\u2009\u00b1\u20090.11\u00a0mmol\/L. The absolute decrease in iCa was \u22120.26\u2009\u00b1\u20090.12\u00a0mmol\/L (\u221217.1\u2009\u00b1\u20097.3%) and \u22120.26\u2009\u00b1\u20090.13\u00a0mmol\/L (\u221217.0\u2009\u00b1\u20097.5%) at day 7 and day 14, respectively. Hypocalcemia occurred after 5 pamidronate administrations (13.5%). The use of IV pamidronate for the management of hypercalcemia postburn injury appeared effective in decreasing iCa levels. Future studies are needed to further evaluate the clinical implications of these findings.<\/jats:p>","DOI":"10.1093\/jbcr\/irag081","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T11:42:55Z","timestamp":1779882175000},"page":"1491-1495","source":"Crossref","is-referenced-by-count":0,"title":["Pamidronate Dose Response for Hypercalcemia in Burn-Injured Patients"],"prefix":"10.1093","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2548-9601","authenticated-orcid":false,"given":"Gisoo","family":"Imani","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Cedars-Sinai Medical Center , Los Angeles, CA 90048 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Louie","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of California Davis Medical Center , Sacramento, CA 95817 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sierra","family":"Young","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of California Davis Medical Center , Sacramento, CA 95817 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremiah J","family":"Duby","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of California Davis Medical Center , Sacramento, CA 95817 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"VanAcker","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of California Davis Medical Center , Sacramento, CA 95817 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7465-4555","authenticated-orcid":false,"given":"Jason","family":"Heard","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Burn Surgery & Reconstruction, University of California Davis Medical Center , Sacramento, CA 95817 ,","place":["United States"]},{"name":"Department of Burn Care, Shriners Hospital for Children , Sacramento, CA 95817 ,","place":["United States"]},{"name":"School of Medicine, University of California Davis , Sacramento, CA 95817 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"2026090808592406400_ref1","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab048.398","article-title":"Hypercalcemia due to immobilization","volume":"5","author":"Ahamed","year":"2021","journal-title":"J Endocr Soc"},{"key":"2026090808592406400_ref2","first-page":"e5","article-title":"Burn-induced bone loss: importance, mechanisms, and management","volume":"8","author":"Klein","year":"2006","journal-title":"J Burns Wounds"},{"key":"2026090808592406400_ref3","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.burns.2009.05.001","article-title":"Hypercalcaemia and acute renal failure after major burns: an under-diagnosed condition","volume":"36","author":"Kohut","year":"2010","journal-title":"Burns"},{"key":"2026090808592406400_ref4","volume-title":"Hypercalcemia","author":"Sadiq","year":"2024"},{"key":"2026090808592406400_ref5","volume-title":"Zoledronic Acid Injection: Prescribing Information","author":"U.S. Food and Drug Administration","year":"2016"},{"key":"2026090808592406400_ref6","doi-asserted-by":"publisher","first-page":"483","DOI":"10.4103\/1947-2714.170600","article-title":"Hypercalcemia of malignancy: an update on pathogenesis and management","volume":"7","author":"Mirrakhimov","year":"2015","journal-title":"N Am J Med Sci"},{"key":"2026090808592406400_ref7","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2020-241386","article-title":"Extreme hypercalcaemia caused by immobilisation due to acute spinal cord injury","volume":"14","author":"Tettero","year":"2021","journal-title":"BMJ Case Rep"},{"key":"2026090808592406400_ref8","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1007\/pl00004164","article-title":"Bisphosphonates: pharmacology, mechanisms of action and clinical uses","volume":"9","author":"Russell","year":"1999","journal-title":"Osteoporos Int"},{"key":"2026090808592406400_ref9","volume-title":"Pamidronate Disodium Injection and Pamidronate Disodium for Injection: Prescribing Information","year":"2025"},{"key":"2026090808592406400_ref10","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.43070","article-title":"Hypercalcaemia of immobility in critically ill patients: case series","volume":"7","author":"Aljeaidi","year":"2023","journal-title":"Cureus"},{"key":"2026090808592406400_ref11","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1097\/BCR.0B013E3181493240","article-title":"Hypercalcemia in patients in the burn intensive care unit","volume":"28","author":"Sam","year":"2007","journal-title":"J Burn Care Res"},{"key":"2026090808592406400_ref12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/PHM.0000000000001907","article-title":"Immobilization-related hypercalcemia in a COVID-19 patient with prolonged intensive care unit stay","volume":"101","author":"Mesland","year":"2022","journal-title":"Am J Phys Med Rehabil"},{"key":"2026090808592406400_ref13","doi-asserted-by":"publisher","first-page":"A202","DOI":"10.1210\/jendso\/bvab048.411","article-title":"Immobilization hypercalcemia (IH) in an adult after spinal cord injury","volume":"5","author":"Sibai","year":"2021","journal-title":"J Endocr Soc"},{"key":"2026090808592406400_ref14","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s00198-004-1731-1","article-title":"The efficacy of the acute administration of pamidronate on the conservation of bone mass following severe burn injury in children: a double blind, randomized, controlled study","volume":"16","author":"Klein","year":"2005","journal-title":"Osteoporos Int"}],"container-title":["Journal of Burn Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbcr\/advance-article-pdf\/doi\/10.1093\/jbcr\/irag081\/68424307\/irag081.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbcr\/article-pdf\/47\/5\/1491\/68424307\/irag081.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbcr\/article-pdf\/47\/5\/1491\/68424307\/irag081.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:59:30Z","timestamp":1788872370000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbcr\/article\/47\/5\/1491\/8697372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":14,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,28]]},"published-print":{"date-parts":[[2026,9,8]]}},"URL":"https:\/\/doi.org\/10.1093\/jbcr\/irag081","relation":{},"ISSN":["1559-047X","1559-0488"],"issn-type":[{"value":"1559-047X","type":"print"},{"value":"1559-0488","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,5,28]]}}}